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Mitigating the financial effects of tuberculosis requires more 
than expansion of services 
Reducing poverty and health inequality remains a global 
imperative, enshrined in the United Nation’s Sustainable 
Development Goals. Irrespective of country of origin or 
residence, poorer people have increased likelihood of ill 
health, malnutrition, and limited access to health care.1 
Few diseases better illustrate the association between 
health and wealth than tuberculosis, which is the 
archetypal disease of poverty. 
Tuberculosis is well recognised to be socially 
determined, and control will only be achieved through 
a multifaceted and holistic response that encompasses 
diagnosis, treatment, employment, nutrition, and 
housing.2 The financial effects of accessing tuberculosis 
care, however, has only begun to garner attention in the 
past few decades.3 
The costs of accessing care to households affected 
by tuberculosis include direct costs, such as those for 
medicines, clinics, food, and travel, and indirect costs, 
such as lost income. Research from Peru defined these 
costs as being catastrophic when they amounted to 
20% or more of a tuberculosis-affected household’s 
annual income, because they were independently 
associated with a person with tuberculosis from that 
household being lost to follow-up, dying, or having 
recurrent disease.5 WHO’s End TB Strategy6 recognises 
that averting these catastrophic costs could potentially 
improve tuberculosis control, and mandates that “zero 
TB-affected households should face catastrophic costs 
by 2025”. 
In The Lancet Global Health, Stéphane Verguet and 
colleagues7 report a modelling study of the effects 
of expanding tuberculosis services on averting 
catastrophic costs to tuberculosis-affected households 
in India and South Africa. They assessed three different 
scenarios of tuberculosis control: improved treatment 
of drug-sensitive tuberculosis; improved treatment 
of multidrug-resistant tuberculosis; and expanded 
access to services (all individuals who seek care being 
screened for tuberculosis symptoms; South Africa 
only). The outcomes were compared with a base case, 
which assumed that coverage and treatment success 
rates at start of the study would be maintained at a 
constant from 2016 to 2035. They used extended 
cost-effectiveness analysis as a complement to their 
model to estimate the differential effects of the 
scenarios across socioeconomic quintiles. 
The findings suggest that aggressive expansion of 
tuberculosis services would avert cases of catastrophic 
costs of patients with drug-sensitive and multidrug-
resistant tuberculosis by 5–6% and 1%, respectively, in 
India, and by 7–19% and 6–18%, respectively, in South 
Africa. The addition of improved access to tuberculosis 
services in South Africa would avert 5–20% of cases of 
catastrophic costs, although the gains would be long 
term and not seen for 5–10 years. The extended cost-
effectiveness analysis showed that catastrophic costs 
were most common in the lowest income quintile 
(30–40% in India and 80% in South Africa), but that 
with service expansion this quintile would contain the 
highest proportion of averted cases of catastrophic 
costs. 
The study has some limitations. First, the number 
of cases of catastrophic costs might have been 
underestimated because indirect costs were calculated 
from income lost while seeking diagnosis rather 
than throughout illness and treatment.5 Second, 
socioeconomic strata were calculated as income 
quintiles, which for poverty is a relatively insensitive 
measure compared with other multidimensional 
indices. Third, as acknowledged by Verguet and 
colleagues, their model assumed only one case of 
tuberculosis per household, which might have diluted 
the disproportionate effect of cases being clustered in 
the poorest households. Nevertheless, policy makers 
and managers in national tuberculosis programmes 
should heed the authors’ conclusions that expansion of 
tuberculosis services alone would lead to only modest 
reductions in households affected by catastrophic 
costs, and that future tuberculosis control strategies 
should incorporate social protection to enhance their 
effectiveness, especially for the poorest households. 
The study by Verguet and colleagues7 is a useful 
contribution to the literature. Other modelling analyses 
have suggested that investment in social protection 
along with tuberculosis prevention and treatment 
programmes could potentially reduce tuberculosis 
See Articles page e1123
Comment
e1057 www.thelancet.com/lancetgh   Vol 5   November 2017
burden, especially for vulnerable groups.8,9 Empirical 
data, however, are scarce, with only one randomised 
controlled trial of a social protection intervention 
(integrating social support with conditional cash 
transfers) for 282 tuberuclosis-affected households 
in 32 Peruvian shanty towns.9 This trial showed 29% 
reduction in catastrophic costs and an increase in 
patients’ likelihood of tuberculosis treatment success.10,11 
Much needed data are being generated by the WHO 
survey to measure catastrophic costs, which is currently 
being rolled out in various sentinel countries and 
could be used to refine further modelling studies like 
that of Verguet and colleagues. This new knowledge 
is being appropriately linked with interdisciplinary 
collaborations, including the Social Protection Action 
Research and Knowledge Sharing network, which aim to 
generate new research ideas in this underfunded area, 
consolidate existing evidence, and inform policy and 
practice. 
Much remains to be done. From a broader long-term 
policy and practice perspective, improved delivery of 
health care and access to national social protection 
and poverty-reduction schemes and working towards 
universal health coverage would be likely to decrease 
financial effects on patients with tuberculosis and other 
illnesses. From a more immediate research-focused 
perspective, stonger evidence is needed in the following 
areas: the most appropriate study designs for assessing 
social protection for households affected by tuberculosis 
(eg, modelling, cluster-randomised trials, and pragmatic 
operational studies); the optimum interventions for 
delivering social protection (eg, combinations of 
nutritional, psychosocial, and economic support, and 
poverty reduction vs cost-mitigation strategies); and 
the differential cost-effectiveness of such interventions 
for groups at most risk of incurring catastrophic costs 
(eg, impoverished households, people with multidrug-
resistant tuber culosis, or people without homes). 
Verguet and colleagues’ findings7 provide a stark 
reminder of the importance of a concerted global 
effort to eradicate the financial effects of tuberculosis; 
without intervention, 20 million people—similar to 
the population of New Delhi—could incur tuberculosis-
related catastrophic costs in India between 2016 and 
2035. Thus, catastrophic costs of tuberculosis are not 
small change. Rather, they are a public health emergency 
in urgent need of attention.
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